{
  "document_id": "HOUSE_OVERSIGHT_028419",
  "filename": "IMAGES-009-HOUSE_OVERSIGHT_028419.txt",
  "text": "dentifier\":\" anf-body-\n\n31\", \"inlineTextStyles\": [{\"range\":{\"lengt\nim}, {\"range\"™:{\"Llength\":226, \"start\":0},\"t\nbody\", \"role\":\"body\", \"text\":\"In 2000, the\nthat it had evidence the company was imp\ncancers as well as to promote a feeling\n\npatients.\",\"type\"™: \"text \"}, {\"identifier\":\n32\",\"inlineTextStyles\": [{\"range\": {\"lengt\nim}, {\"range\":{\"Llength\":175, \"start\":0},\"t\n\nh\":226,\"start\":0},\"textStyle\":\" anf-ts-\nextStyle\"™:\" anf-ts-1\"}],\"layout\"™:\"default-\nagency issued a formal warning letter, saying\nroperly marketing Thalomid for a variety of\nof a€egeneral well-beinga€ in cancer\n\"_anf-body-\nh\":175,\"start\":0},\"textStyle\":\" anf-ts-\nextStyle\"™:\" anf-ts-1\"}],\"layout\":\"default-\n\nbody\", \"role\": \"body\", \"text\": \"a€ePerhaps more than for any other available drug, the need\n\nto provide and distribute thalidomide re\nthe agency wrote in the\n\nletter.\", \"type\": \"text \"}, {\"additions\":[{\"\n16284/000100515001000229/0001005150-01-\n000229.txt\", \"range\": {\"length\":20,\"start\"\n33\",\"inlineTextStyles\": [{\"range\":{\"lengt\ni\"},{\"range\"™:{\"Llength\":517,\"start\":0},\"t\nbody\", \"role\": \"body\", \"text\":\"Over the nex\n\nsponsibly is essential to the public health, a4€\nURL\": \"https://www.sec.gov/Archives/edgar/data/8\n7286}, \"type™:\"link\"}],\"identifier\":\" anf-body-\n\nh\":517,\"start\":0},\"textStyle\":\" anf-ts-\nextsStyle\"™:\" anf-ts-1\"}],\"layout\"™:\"default-\n\nt few years, however, Mr. Hugin and other top\n\nxecutives repeatedly referred to Thalomid 4€\" and later Revlimid 4€\" as the key to\n\nCelgenead€™s financial future, even thoug\nthe drugs to treat certain cancers until\nthat 92 percent of Thalomidad€™s prescrip\nat an investor conference in 2004, Mr. H\nis the financial engine that drives us.4\n34\", \"inlineTextStyles\": [{\"range\":{\"lengt\n1\"},{\"range\"™:{\"Llength\":171,\"start\":0},\"t\nbody\", \"role\": \"body\", \"text\":\"Celgene has\n\nsaying it settled the lawsuit in 2017 to\nof protracted litigation.ad€\", \"type\": \"tex\n35\", \"“anlineTextstyles\": [{\"range\":{\"lengt\n1\"},{\"range\":{\"length\":186, \"start\":0},\"t\n\nh it would not get formal approval to market\n2005 and 2006. In 2001, the company reported\ntions were being written to treat cancer, and\nugin said, a€eThalomid is important, because it\n\n€\", \"type\"™:\"text\"}, {\"identifier\":\" anf-body-\nh\":171,\"start\":0},\"textStyle\":\" anf-ts-\nextsStyle\"™:\" anf-ts-1\"}],\"layout\"™:\"default-\n\ndenied that it engaged in illegal marketing,\navoid the uncertainty, distraction and expense\n\nt\"}, {\"identifier\":\" anf-body-\nh\":186,\"start\":0},\"textStyle\":\" anf-ts-\nextStyle\"™:\" anf-ts-1\"}],\"layout\":\"default-\n\nbody\", \"role\":\"body\", \"text\": \"The incredib\npromising treatments for multiple myelom\npatients a year, was a windfall for\nCelgene.\", \"type\": \"text\"}, {\"additions\": [{\ns/revlimid-long-\n\nform.pdi\", \"range\": {\"length\":17,\"start\":2\n36\", \"inlineTextStyles\": [{\"range\":{\"lengt\n1\"},{\"range\":{\"Llength\":218, \"start\":0},\"t\nbody\", \"role\": \"body\", \"text\":\"Introduced t\nRevlimid, a closely related derivative o\n2017, Celegene had raised the price of a\n$16,000.\",\"type\"™:\"text\"}, {\"identifier\"™:\"\n\nle demand for Thalomid, and later Revlimid, as\na, a disease that affects more than 30,000\n\n\"URL\": \"https://media.celgene.com/content/upload\n\n00}, \"type™:\"link\"}],\"identifier\":\" anf-body-\nh\":218,\"start\":0},\"textStyle\":\" anf-ts-\nextsStyle\"™:\" anf-ts-1\"}],\"layout\"™:\"default-\n\no the market in 2006, a monthda€™s supply of\n\nf thalidomide, initially cost about $6,000. By\nmontha€™s supply to more than\n\nanf-heading4-\n\n3\", \"Layout\": \"heading4\", \"role\": \"heading4\", \"text\":\"A brutal battle to fend off generic\n\ndrug makers\", \"type\": \"text\"}, {\"identifier\n37\", \"inlineTextStyles\": [{\"range\": {\"lengt\nim}, {\"range\"™:{\"Length\":328,\"start\":0},\"t\nbody\", \"role\":\"body\", \"text\":\"The company\n\n\":\" anf-body-\nh\":328,\"start\":0},\"textStyle\":\" anf-ts-\nextstyle\"™:\" anf-ts-1\"}],\"layout\"™:\"default-\n\nwas able to aggressively raise prices in part\n\nas a result of its legal monopoly. Under\ncan exclusively market a drug for up to\n\nwith any patents, the market opens to ge\nprecipitously.\", \"type\": \"text\"}, {\"identift\n38\", \"inlineTextStyles\": [{\"range\":{\"lengt\nim}, {\"range\"™\":{\"Llength\":113, \"start\":0},\"t\nbody\", \"role\":\"body\", \"text\":\"To protect t\nmounted an aggressive campaign to extend\nmonopoly.\", \"type\": \"text\"}, {\"identifier\"™:\n39\",\"inlineTextstyles\": [{\"range\":{\"leng\n1\"},{\"range\": {\"length\":269, \"start\":0},\"\nbody\", \"role\": \"body\", \"text\": \"4€eTheyae™ve\ndrug and to build as many walls around i\npresident for federal government affairs\nthe generic drug industryde™s lobbying g\n40\", \"inlineTextStyles\": [{\"range\":{\"lengt\ni\"},{\"range\"™:{\"length\":145, \"start\":0},\"t\n\nfederal regulations, a pharmaceutical company\nseven years. Once that period expires, along\nneric competition and prices typically fall\n\nier\":\"_ anf-body-\nh\":113,\"start\":0},\"textStyle\":\" anf-ts-\nextsStyle\"™:\" anf-ts-1\"}],\"layout\"™:\"default-\n\nhe profits from Revlimid and Thalomid, Celgene\nits\n\n\"_anf-body-\nh\":269,\"start\":0},\"textStyle\":\" anf-ts-\nextsStyle\"™:\" anf-ts-1\"}],\"layout\":\"default-\n\ngone to pretty great lengths to protect that\n\nt as they can,a4€ said Michael Brzica, the vice\nat the Association for Accessible Medicines,\nroup.\", \"type\": \"text\"}, {\"identifier\":\" anf-body-\nh\":145,\"start\":0},\"textStyle\":\" anf-ts-\nextsStyle\"™:\" anf-ts-1\"}],\"layout\"™:\"default-\n\nbody\", \"role\": \"body\", \"text\":\"Celgene has been repeatedly accused of restricting access\n\nto samples of its drugs, which generic c\n\nompanies need to test their competing\n\nHOUSE_OVERSIGHT_028419",
  "metadata": {
    "original_filename": "IMAGES-009-HOUSE_OVERSIGHT_028419.txt",
    "source_dataset": "huggingface:tensonaut/EPSTEIN_FILES_20K",
    "character_count": 5392,
    "word_count": 589,
    "line_count": 166,
    "import_date": "2025-11-19T21:47:47.010253",
    "prefix": "IMAGES-009"
  }
}